OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies said the U.K. MHRA aligned with its plan to initiate a confirmatory Phase 3 trial of OST-HER2 in mid-Q4 2026, using the existing Phase 2 drug product following requalification. The company expects to submit a Conditional Marketing Authorisation Application in the coming weeks and said MHRA participants recommended U.K. leadership of a Project Orbis review alongside the FDA and EMA. OSTX is also pursuing FDA accelerated-approval-related pathways, with decisions pending on RMAT, Rolling Review and CNPV as its BLA filing, initiated in Q1 2026, targets completion in Q4 2026.

Analysis

OSTX’s investable inflection is not the advisory interaction itself, but whether it converts into a review pathway that materially shortens time to commercial revenue in an ultra-rare indication. The U.K. registry access can reduce uncertainty around external-control credibility, a central valuation issue for single-arm oncology programs; however, historical comparators rarely eliminate FDA concerns over selection bias, endpoint ascertainment, and treatment-era differences. The confirmation that a previously missing patient remains alive is directionally helpful but should not drive the thesis absent full updated intent-to-treat survival data and censoring detail.

Near term, the stock is likely to trade on regulatory-designation headlines and perceived voucher optionality rather than fundamentals, creating high volatility around FDA decisions over the next 1-3 months. The more consequential catalyst is the adequacy of the completed filing package and any acceptance/review-clock confirmation; a conditional U.K. path does not assure U.S. accelerated approval, and a new confirmatory study beginning late 2026 pushes definitive validation well beyond the initial commercial-access window. Consensus may overvalue Project Orbis as a probability enhancer: synchronized review can improve process efficiency, but it does not harmonize evidentiary standards. Falsify a constructive setup if FDA declines expedited designations, requests material clinical-data remediation, or if updated survival outcomes fail to show durability versus the external-control benchmark.

Key Decisions for Investors

• Do not chase OSTX on the release; treat it as a regulatory-event watch rather than a core long until the company discloses filing acceptance, review type, and a transparent updated survival dataset. Entry should follow confirmation of a defined review clock, not advisory language.
• For biotech-risk capital, consider a small long OSTX only after BLA acceptance and before the first formal FDA designation decision, sized for binary loss risk. Target a 2-3x upside only if expedited review and a credible early-access path are confirmed; exit on refusal-to-file, major information request, or an FDA statement requiring randomized evidence before approval.
• Monitor OSTX financing runway, cash burn, and share-count changes before adding exposure. A late-2026 confirmatory-study launch plus commercialization preparation could force dilutive financing even if regulatory sentiment remains positive; a discounted equity raise would be a better entry point than the current press-release catalyst.
• Avoid using a broad biotech ETF hedge as the primary risk control: OSTX’s dominant risks are idiosyncratic regulatory and external-control-data risks. If holding a position, hedge through position sizing or defined-risk options only if liquid strikes and implied volatility permit acceptable premium.